Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 148 participants.

Also called NCT02542319

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 148 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02542319
Other papers using this trial's data
  • The Effect of Magnesium Supplementation on Vascular Calcification in CKD: A Randomized Clinical Trial (MAGiCAL-CKD) Journal of the American Society of Nephrology : JASN, 2023-05-01 DOI, PubMed 36749131, PMC10125639 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark, Norway (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02542319. Randomized; triple masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2020-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease
Acronym
MagiCal-CKD
Condition
Vascular Calcification
Condition
Uremic Osteodystrophy
Intervention (Dietary supplement)
Mablet 360 mg
Intervention (Dietary supplement)
Placebo
Lead sponsor
Nordsjaellands Hospital (class: other)
Collaborator
Herlev Hospital (class: other)

Record details

Record id
cardio:ct-nct02542319
Content hash
8688c9877cd601c7bcd7124fafada1631be3dbcb04129dabcda2e2b709987172